By Fineline Cube 
Navi Therapeutics (Shanghai) Co., Ltd. announced the successful completion of two financing rounds — Angel and Series A — with aggregate funding reaching several hundred million RMB. The Angel round was led by Trinity Innovation Fund, with participation from Oriza Seed and Fenglei Capital. The Series A round was co‑led by Legend Capital and Bayland Capital, with participation from YuanBio Venture Capital and other leading institutional investors and strategic backers; all existing Angel‑round investors followed on with additional commitments. Proceeds will support the advancement of the company’s differentiated antibody‑drug conjugate (ADC) pipeline toward first‑in‑human trials.
Funding Milestone
| Item | Detail |
|---|---|
| Rounds | Angel + Series A |
| Aggregate Size | Several hundred million RMB |
| Angel Round | Led by Trinity Innovation Fund; Oriza Seed, Fenglei Capital participating |
| Series A | Co‑led by Legend Capital and Bayland Capital; YuanBio Venture Capital and others participating |
| Follow‑On | All Angel‑round investors committed additional capital |
| Announcement Date | 18 Aug 2026 |
Company & Technology Profile
- Focus: Development of differentiated next‑generation ADCs for solid tumor indications.
- Antibody Platform: NaviMIG multi‑specific antibody platform.
- Payload Platform: ReviLOAD payload platform.
- AI Integration: Artificial intelligence deeply integrated into the entire drug R&D process.
- Pipeline: Two lead programs with first‑in‑class (FIC) potential.
Development Roadmap
- Near‑Term Milestone: IND submissions planned for the first half of 2027 for the two lead pipelines.
- Platform Strategy: Multi‑specific antibody design combined with differentiated payload technology aims to improve therapeutic index versus current‑generation ADCs.
- AI‑Driven R&D: AI integration across discovery and development is intended to accelerate candidate optimization and de‑risk progression.
Market Impact & Outlook
- ADC Landscape: Antibody‑drug conjugates remain one of the hottest modalities in oncology, with strong deal‑making and clinical momentum in solid tumors globally.
- Differentiation: The combination of the NaviMIG and ReviLOAD platforms with AI‑native R&D positions Navi Therapeutics in the emerging wave of next‑generation ADC developers.
- Investor Signal: Co‑leadership by Legend Capital and Bayland Capital, alongside full Angel‑round follow‑on, reflects sustained institutional confidence in the company’s platform and pipeline potential.
- Strategic Positioning: With capital secured and IND filings targeted for H1 2027, Navi is positioned to convert its two FIC‑potential programs into clinical‑stage assets within the next year.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding IND timelines and clinical development expectations for Navi Therapeutics’ pipeline. Actual results may differ due to risks including preclinical outcomes, regulatory review and competitive dynamics.-Fineline Info & Tech